Sunday APOLLO Phase 3 results webcast announcement lifts Disc Medicine 21% before data release
- Company GlobeNewswire release posted Sunday, October 18, at 5:00 p.m. ET
- It scheduled an 8:00 a.m. Monday webcast covering APOLLO topline results
- Shares repriced immediately when pre-market trading opened at 4:00 a.m. ET
- No efficacy or safety results were public by the 4:05 a.m. snapshot
- APOLLO is pivotal because February's FDA rejection specifically required these trial results
- June FDA discussions established successful APOLLO data could support resubmission and traditional approval
- The 21.1% gap exceeds four times IRON's 4.4%-5.0% normal daily range
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.